InsidersTradesSigma
Total declarations
Companies
▲ Purchases (19 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
19
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-26.3%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by ROSENWALD LINDSAY A MD, Director. Officer active across 5 companies, notably Checkpoint Therapeutics, Inc.. In total, 38 reports have been recorded. Breakdown: 19 buys · 0 sell. Total volume traded: €6.7m. History available since 10 June 2021. The latest transaction was filed on 1 January 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations38 total
10,000 sharesCommon Stock, $0.0001 par valueSEC:0001104659-26-078266:0
454,153 shares0Common stock, par value $0.001SEC:0001415889-25-000400:0
12,638 shares0COMMON STOCKSEC:0001104659-24-129526:0
763,359 shares@ US$1.8420.5% of flowCommon stock, par value $0.001SEC:0001415889-24-023957:0
Ideal exit: 20 Jun 2025 (T+270)
5,000 shares@ US$7.48350.6% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-079855:0
Ideal exit: 7 Apr 2025 (T+270)
5,000 shares@ US$7.39420.6% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-079100:0
Ideal exit: 5 Apr 2025 (T+270)
9,728 shares0Common Stock, $0.0001 par valueSEC:0001104659-24-078968:0
5,000 shares@ US$7.35290.6% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-078786:0
Ideal exit: 4 Apr 2025 (T+270)
20,000 shares@ US$1.63620.5% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-076591:0
Ideal exit: 25 Mar 2025 (T+270)
10,000 shares@ US$1.75890.3% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-063455:0
Ideal exit: 10 Feb 2025 (T+270)
32,051 shares0COMMON STOCKSEC:0001104659-24-062664:0
10,000 shares@ US$3.049.4% of flowCommon Stock, $0.0001 par valueSEC:0001104659-24-039354:0
Ideal exit: 20 Dec 2024 (T+270)
20,000 shares@ US$3.4021.0% of flowCommon Stock, $0.0001 par valueSEC:0001104659-24-038431:0
Ideal exit: 17 Dec 2024 (T+270)
50,000 shares@ US$2.37541.8% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-002464:0
Ideal exit: 1 Oct 2024 (T+270)
216,465 shares0COMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-000898:0
1,567,515 shares@ US$1.7040.5% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-23-119188:0
Ideal exit: 10 Aug 2024 (T+270)
100,000 shares@ US$0.28331.3% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-23-104099:0
Ideal exit: 22 Jun 2024 (T+270)
348,675 shares@ US$0.72100.0% of flowCommon StockSEC:0001437749-23-025643:0
Ideal exit: 4 Jun 2024 (T+270)
100,000 shares@ US$2.2369.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-23-099229:0
Ideal exit: 2 Jun 2024 (T+270)
10,000 shares@ US$11.751.8% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-23-093700:0
Ideal exit: 13 May 2024 (T+270)
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079114:0
17,483 shares0COMMON STOCKSEC:0001104659-23-071759:0
4,094 shares@ US$0.73934.8% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040932:0
Ideal exit: 13 Dec 2022 (T+270)
2,395,209 shares@ US$0.83530.3% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-23-021617:0
Ideal exit: 7 Nov 2023 (T+270)
4,264 shares@ US$0.730.0% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-23-001103:0
25 of 38 declarations
About ROSENWALD LINDSAY A MD
Lindsay A. Rosenwald, MD, is President, CEO, and Chairman at Checkpoint Therapeutics, Inc., Mustang Bio, Inc., and Fortress Biotech, Inc. He is responsible for the strategic and operational direction of these companies, leveraging his expertise in biotechnology to drive innovation and growth.
